Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients

Ain Shams University

Status: Enrolling

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT05733026

BC-Genetics

Details and patient eligibility

About

Recent advances in technologies, such as microarray and high-throughput sequencing, represented a deeper understanding of molecular biology, especially noncoding RNA (ncRNA). It was found that there are only <2 % of the total genome sequence as protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the past, non-protein-coding RNAs were known as "transcription noise," but now it is obvious that ncRNAs play a crucial regulatory role in cell differentiation and organism growth and metabolism.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic and localized breast cancer patients treated with Doxorubicin among chemotherapeutic protocol.
• Measurable disease.
• Age of 18 years to 80 years.
• The women of childbearing age must use an effective contraception for the duration of the study.

Exclusion criteria

• Breast cancer patients who had undergone radiotherapy or chemotherapy.
• Pregnant and lactating females.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents used.
• Any other medical or psychiatric condition or severe or chronic laboratory abnormality making the inclusion of the patient in the study inappropriate in the opinion of the investigator.

Trial design

200 participants in 2 patient groups

1

Description:

Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment

2

Description:

Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment